top of page


Chair (Interim), President & CEO

Dr. Mettinger has more than 35 years of experience as an executive in the life science industry, and has been involved with the successful development of new therapeutics, including a number of oncology, hematology, cardiovascular and CNS drugs and biologic products approved by regulatory agencies worldwide. Dr. Mettinger is the Principal and Founder of Progressive Clinical partners and helped accelerate and facilitate approvals of a novel oral breakthrough therapy in lymphoma and leukemia, leading to the USD21B market cap and acquisition. He was also a consultant to Philantropist /Investor Edward Bosarge (Capital Technologies, Houston and Tissue Genesis LLC, Honolulu) helping establish a franchise in cellular therapeutics / Regenerative Medicine. He served as Medical Director of Hematology and as Deputy General Manager of the cardiovascular business unit, of bi  (Pharmacia, now part of Pfizer), in Sweden, as Medical Director/ Executive Director at IVAX Corporation (acquired by Teva); Chief Medical Officer/Senior Vice President at SuperGen, (Astex, acquired by Otsuka); Chief Medical Officer at Oncolytics Biotech Inc, AB ; co-founder and past President of the Swedish Stroke Society, a 10,000-member stroke research and patient support organization. Dr. Mettinger received his M.D. from the University of Lund in Sweden and his Ph.D. in Hematology/Neurology from, and is a former Associate Professor of, the Karolinska Institutet, the home of the Nobel Prize in Medicine and Physiology  in Stockholm.



Vice Chairman, Director


Sven Andréasson has more than 40 years’ experience as an executive in the life science industry. He started his career at Kabi, Stockholm, where he became CEO for the German, UK and Belgian subsidiaries. He subsequently became head of the Biopharmaceutical division responsible for human growth hormones, blood plasma products, and LMW heparin/ thrombolytic cardiovascular products. After the acquisition of Pharmacia in 1989 he became President of Pharmacia International in Brussels, Belgium and later Pharmacia SA, Paris, France (today part of Pfizer). From 1999 he served for nine years as the President and CEO of Active Biotech, Lund Sweden, a publicly traded company developing innovative products for autoimmune diseases including multiple sclerosis (partnered with TEVA) and for various cancers. He subsequently became CEO of Beta-Cell NV, in Brussels, a company developing cell-based treatments for diabetes. In February 2012 he became CEO of Isconova AB, a vaccine development company acquired by Novavax Inc, Rockville, MD, where he became Senior VP, Corporate Development. Sven Andréasson has an MSc in business administration and finance from the Stockholm School of Economics..

svenAndreassonNew Picture.jpg

                            DANIEL QUINTERO

       Secretary, Legal Counsel, Director

Daniel Quintero has a long and distinguished career in Silicon Valley and the Bay area. He is a Founding Partner and Managing Partner of Prometheus Partners LLP, a diverse group of accomplished former Big Law Partners and Executive In House counsel committed to supporting innovation.  Mr. Quintero was previously the General Counsel and Corporate Secretary for Sony Optiarc America Inc., where he concurrently served as Senior Managing Counsel and Director for Sony Electronics Inc. and managed Sony's Silicon Valley law department operations. His responsibilities included advising executive management and the board of directors of a multi-national corporation, and negotiating and structuring multi-million and multi-billion dollar engagements. Mr. Quintero is largely well respected for his views on innovation and technology and was named one of California’s Top 20 General Counsel by the Daily Journal.  Mr. Quintero received his undergraduate degree from the University of San Francisco (USF), and received his law degree from Berkeley Law (Boalt Hall), University of California at Berkeley.

Daniel Quintero.jpg


Director, CFO




Bruce Phillips ,Phillips has a long and distinguished career in the accounting industry for more than 3o years. After graduating from the College of William & Mary he joined Arthur Young and became an accounting manager for Ernst & Young. In 1992, he became a Founding Partner, and later CEO of HPC (Harshman, Phillips & Company) which for decades operated as a traditional accounting firm in Atlanta. At the annual accounting convention In 2011 he met Rodney Drury, the founder of XERO, the pioneer of the cloud based accounting technology platform, Soon HPC became a Platinum Partner of XERO and leading cloud based accounting firm which grew to becomea full service provider working remotely all over United States, from California, to Florida and New Hampshire and with an increasing number of clients all over the globe. After the merger with Aprio Cloud in 2018, Bruce became Managing Director and Partner, Head of Cloud Accounting Solutions,in the merged company operating globally.

Bruce Phillips.jpg

Dr. Kent Persson, PhD

Cofounder, Director, Senior Scientific Advisor

Dr. Persson is an experienced cell and molecular biologist with 20  years research expertise in genomics and molecular-cellular biology. He holds a Ph.D. in Molecular Biology from Umeå University in Sweden and did a Postdoctoral Fellowship in gene expression research at the University of California San Francisco. After postdoctoral work, Dr. Persson served as Senior Scientist in the Gene Expression Division of Bio-Rad Laboratories in California, participated in research and development of gene expression tools and led technical training in genetic analysis work. Returning to Sweden, Dr. Persson has been working for Octapharma AB in Stockholm. First as a Senior Scientist at the Biopharmaceutical Division where he oversaw Cell and Molecular Biology and manages process analysis development, introducing new molecular biology techniques including development of technologies in cell culturing, recombinant protein production, and molecular biological IND filings. Later Dr. Persson served as a Project Manager at Octapharma’s Quality Unit. Within the project he oversaw development, implementation and regulatory submission for assays to serve Octapharma’s recombinant production. Now Dr. Persson worked as Senior Analytical Specialist working with various projects at the Octapharma Quality Unit. In January 2023 he joined  AstraZeneca as a Sr.  Quality Assurance Project Specialist.

Kent Persson.jpg


bottom of page